NCT07751744: Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
- State
- Not started
- Phase
- Phase 1 and Phase 2
- People
- 113 planned
- Started
- 1 Apr 2028
- Primary completion
- 31 Mar 2030
- Arms
- Arm 1 - Dose-Escalation Phase, Arm 2 - High-Grade Glioma Expansion Cohort, Arm 3 - Brain Metastases Expansion Cohort, Arm 4 - Leptomeningeal Disease Expansion Cohort
- Results
- None posted
- 7 Aug 2026: Trial registered